Runner's high, cannabis, and endurance running

A Behavioral Phenotype, Not A Lab Value

Ultrarunners describe it after long aerobic blocks, often past the first hour, when pace settles and the internal argument quiets. Mood lifts. Discomfort fades into background noise. That profile shows up in field studies of cannabis-assisted runs and in sober treadmill work when endocannabinoids rise.

Neuroscience now treats the runner's high as a multi-system event. Dopamine and serotonin shift. Endogenous opioids may still modulate affect. The endocannabinoid system is the line with the strongest human evidence for the core euphoria and anxiolysis.

How The Science Moved

CB1, CB2, Anandamide, And 2-AG

• CB1 receptors sit heavily in brain and nervous tissue. Anandamide (AEA) binds here and is linked to euphoria, focus, and stress modulation.
• CB2 receptors appear in immune cells and muscle. They modulate inflammation and recovery signaling.
• 2-Arachidonoylglycerol (2-AG) is the other major endocannabinoid. Post-exercise responses are less consistent across studies than AEA.
• FAAH and MAGL enzymes degrade AEA and 2-AG. Exercise shifts both production and clearance.

Why Anandamide Matters More Than Endorphins In This Debate

Anandamide is lipophilic. It crosses the blood-brain barrier. Beta-endorphin does not cross freely. That biochemical fact does not erase opioids from the story, but it explains why peripheral endorphin rises did not match subjective high reports for decades.

CB1 activation in the brain can raise dopamine and reduce anxiety during sustained effort. CB2 activation in muscle and immune tissue may reduce inflammatory signaling after hard blocks. Both paths matter on a 100-mile start line.

Cannabinoid Blockade In Mice

Fuss et al. (PNAS 2015) showed that mice with blocked cannabinoid receptors lost exercise-induced analgesia and sedative effects in running wheels. Blocking opioid receptors did not produce the same loss.

Raichlen et al. (J Exp Biol 2012) found exercise-induced endocannabinoid increases in cursorial mammals (humans and dogs) but not in ferrets. Species that evolved to run long distances show the pattern. Species that do not, do not.

Human Opioid Blockade

Fuss et al. (Psychoneuroendocrinology 2021) gave trained runners naltrexone to block opioid receptors, then had them run. Endocannabinoids still rose. Mood benefits persisted. Opioid blockade did not abolish euphoria or anxiolysis.

Popular articles sometimes write 'endorphins debunked.' That overcorrects. Endorphins still increase with exercise. Some PET work still links central opioid binding to euphoria ratings. The defensible claim is narrower: endocannabinoids are necessary for a major component of the high in humans, not that opioids do nothing.

Marketing that says endorphins were 'never proven' sells clarity. The literature is messier than that.

The Intensity Window

Raichlen et al. (Eur J Appl Physiol 2013) reported significant AEA increases at roughly 70 to 80 percent of age-adjusted maximum heart rate. Low and very high intensities did not show the same pattern in that study.

A 2024 outdoor running study (Sports) found both AEA and 2-AG rose after 60 minutes, with mood improvements modulated by sex, age, and training history. A 2026 marathon and ultramarathon field study (BMC Medicine) reported progressive AEA increases through the race, with elevation still present 45 minutes post-finish. Walking control sessions did not replicate the euphoria profile.

2-AG Is Not As Clean A Marker

Meta-analytic work shows AEA more consistently rises post-exercise than 2-AG. Some studies show biphasic or delayed 2-AG patterns after marathons. Do not treat every endocannabinoid as interchangeable in discussion or in product marketing.

What Surveys Show

YorkWilliams et al. (Front Public Health 2019) reported 81.7 percent of cannabis users in legal states co-used with exercise. Co-users logged about 43 more minutes of exercise per week than non-co-users and reported more enjoyment (70.7 percent), better recovery (78 percent), and more motivation (52 percent).

Zeiger et al. (Sports Health 2020) meta-analyzed over 46,000 athletes and found roughly 23.4 percent reported cannabis use in the past year. Prevalence varies by sport, level, and testing environment.

Weed-Positive Run Clubs And Elite Anecdotes

New York's Rage and Release and similar clubs treat cannabis as a community tool before group miles. Ultrarunner Kate Glavan has spoken publicly about using cannabis through marathon training, including the New York City Marathon. Journalist Josiah Hesse's book Runner's High documented the cannabis-centric running subculture for a general audience.

Survey data contradict the lazy stoner stereotype. Co-users in legal states often report more weekly movement, not less. That does not prove cannabis improves physiology. It may improve adherence, which is a different variable.

Field Runs With Cannabis

Gibson et al. (Cannabis and Cannabinoid Research 2022) had co-users run 3.95 miles with and without cannabis. Cannabis sessions showed more positive affect, enjoyment, tranquility, dissociation, and runner's-high symptoms. Pain scores dropped. Pace was about 31 seconds per mile slower, though that difference was not statistically significant in that sample.

Gibson et al. (Sports Medicine 2024) tested 42 runners on treadmills with ad libitum use of commercial THC and CBD products. Cannabis before running increased positive affect, enjoyment, and runner's-high symptoms. It also increased perceived exertion and breathlessness, especially with THC-forward products.

Time-Trial Power Under THC

MacInnis et al. (J Appl Physiol 2023) found THC impaired 20-minute cycling time-trial mean power regardless of smoked or vaporized route. CBD-only product did not change performance in that protocol.

Kennedy (JSAMS 2017) reviewed acute THC and exercise studies through 2017 and reported no aerobic ergogenic effect, with possible strength reduction and angina at lower workloads in some populations. Charron et al. umbrella review (J Sports Med Phys Fitness 2021) reached similar conclusions for acute cannabis and exercise performance.

Evidence Strength At A Glance

What Each Compound Is Trying To Do

• THC: partial CB1 agonist. Low doses may modulate mood and pain perception. Higher doses raise heart rate, anxiety, and coordination risk. Acute THC trials lean ergolytic on power tests.
• CBD: weak direct CB receptor activity; modulates FAAH and other targets. Human exercise RCTs at 150 mg/day for three weeks showed no time-trial improvement (Bell et al., Eur J Sport Sci).
• CBG: non-intoxicating cannabinoid with preclinical anti-inflammatory and anxiolytic data. Athlete-specific RCTs are sparse.
• Entourage effect: Mechoulam and Ben-Shabat (1998) proposed combined cannabinoids modulate each other. Plausible in vitro. Athletic dose-response in vivo is still mostly marketing plus small trials.

Dose, Route, And Tolerance

Smoked cannabis adds pulmonary load. Edibles and drinks vary in onset. Tolerance in chronic users blunts subjective effects and shifts dose response. Most exercise studies recruit existing users, which inflates positive subjective reports and complicates placebo control.

This article does not prescribe doses. Any product label is a starting point for a conversation with a clinician, not a race plan.

What Co-Users Report On Recovery

YorkWilliams et al. found 78 percent of cannabis co-users in legal states reported better recovery from exercise. That is subjective recall, not a controlled protocol. It aligns with how brands frame post-run gummies and CBD topicals.

Gibson's field work shows pain scores drop during cannabis-assisted runs. Lower perceived soreness is not the same as faster muscle repair or lower creatine kinase on a lab draw.

CB2, Inflammation, And The Mechanism Story

• CB2 receptors in immune tissue and muscle modulate cytokine signaling. Preclinical anti-inflammatory data exist for cannabinoids. Human post-exercise inflammatory panels at athlete-relevant doses are mostly flat in CBD trials.
• Anandamide rise during long runs may contribute to post-session calm and reduced pain perception without any exogenous product. That natural window is the benchmark commercial recovery claims need to beat.
• Sleep quality matters more for ultrarunner recovery than any supplement narrative. THC can shorten sleep latency for some users and suppress REM for others. CBD sleep data are mixed at studied doses.

Where Recovery Claims Hold Up And Where They Don't

Defensible use case: adult non-tested athletes using low-dose products to unwind after easy days, with full awareness that evidence for tissue repair is thin. High-risk use case: THC before a hard descent, in heat, or when next-morning alertness matters for crew and navigation.

Tested athletes face contamination risk on any cannabinoid product. Recovery benefit has to clear both physiology and antidoping reality. A product that might reduce soreness but costs a season is not recovery.

Survey optimism is real. It is not a substitute for peer-reviewed recovery endpoints on the product you are holding.

CBD Recovery Trials

Acute CBD after eccentric muscle damage did not beat placebo on inflammation markers, muscle damage, or fatigue in a 2022 Healthcare trial. An eight-week 50 mg/day CBD study (Nutrients 2023) found no body composition, aerobic fitness, or strength changes versus placebo, with a possible anaerobic peak-power preservation signal that needs replication.

A 2024 systematic review (Nutrients) covering seven studies concluded limited beneficial effect on physiological parameters and limited recovery data overall. Preclinical anti-inflammatory mechanisms exist. Human post-training protocols at studied doses do not yet match the marketing.

Label Accuracy And Strict Liability

Bonn-Miller et al. (JAMA 2017) found 69 percent of online CBD products mislabeled for CBD content, with some containing undeclared THC. WADA and USADA hold athletes strictly liable for what appears in a sample regardless of label claims.

NSF Certified for Sport reduces but does not eliminate contamination risk. Hemp-derived THC products marketed as legal under the 2018 Farm Bill can still produce a positive test. Offfield states this plainly on product pages. Many athletes cannot afford to learn that lesson at a checkpoint.

Cardiovascular And Cognitive Load

• THC can increase heart rate and alter autonomic response during submaximal work. Kennedy (2017) noted angina at lower workloads in some THC exercise studies.
• Technical trail running requires reaction time, foot placement, and descent judgment. Psychoactive doses impair coordination and can increase anxiety at higher THC levels (Gibson 2024 breathlessness and exertion findings).
• Heat and dehydration on ultras compound cardiovascular strain. Adding THC before a hot canyon descent is a different risk profile than a cool treadmill lab.
• Cannabis use disorder is real in a subset of users. WADA cites population abuse prevalence in maintaining THC on the prohibited list.

2025 Prohibited List Essentials

WADA's 2025 list prohibits all natural and synthetic cannabinoids in-competition except cannabidiol (CBD). THC is classified as a Substance of Abuse. The urinary carboxy-THC threshold is 150 ng/mL with a decision limit of 180 ng/mL, raised from 15 ng/mL in 2013 to target in-competition use rather than distant exposure.

Sanctions for a Substance of Abuse violation start at three months ineligibility, reducible to one month with completion of an approved treatment program when use was out-of-competition and unrelated to sport performance. Sha'Carri Richardson's 2021 Olympic Trials positive remains the public reference point for legal state use versus antidoping reality.

Why THC Stays Banned Without Ergogenic Proof

WADA's 2022 cannabis review examined over 2,700 articles. Insufficient evidence supported physiological performance enhancement. Health risk and spirit-of-sport criteria still support the ban. Only two of three WADA criteria are required for listing.

Neuropsychological enhancement 'cannot be excluded' in WADA's language. That is not proof THC makes you faster. It is enough for policy when combined with health and safety concerns.

What Offfield Sells

Offfield's High Performance line includes low-dose hemp-derived delta-9 THC with CBD and CBG, paired with yerba mate caffeine, B vitamins, and electrolytes in drinks. Enhanced line products are THC-free for athletes who want cannabinoids without psychoactive THC. The brand runs Offfield Labs, a beta program that tests formulas with athletes before wide release.

Offfield subscriber survey data on their site reports 67 percent actively training for a race, 96 percent using products with every training session, and 82 percent exercising five days per week. Treat those figures as company-reported, not peer-reviewed.

• OFFFIELD homepage Brand positioning and product catalog.
• Offfield science page Their endocannabinoid and performance claims.
• High Performance Energy Gummies Flagship THC/CBD/CBG gummy product.
• Offfield runner's high article Brand editorial on endocannabinoids and exercise.

Where Their Science Page Is Strong And Where It Overreaches

• Strong alignment: cites Fuss 2021, YorkWilliams 2019, Gibson work, and Dietrich and McDaniel 2004 on exercise-induced endocannabinoids. Those citations match mainstream literature.
• Overreach: 'Endorphins never proven' flattens a nuanced literature. Endorphins rise with exercise; human opioid pathways may still modulate affect.
• Overreach: 'Mimic runner's high' from exogenous cannabinoids is plausible at low doses but not validated in independent RCTs on Offfield's exact formulas and timing.
• Honest friction: product pages warn High Performance items contain THC and may fail drug tests. That clarity matters for tested athletes.

Offfield is not NSF Certified for Sport at time of writing. Tested athletes should treat that as a hard stop unless their federation and employer say otherwise.

Third-Party Coverage

• GreenState athlete review Independent product trial and founder interview.
• The Quality Edit review Early brand profile and hydration stick review.

Rely On The Natural Runner's High If

• You compete under WADA, USADA, NCAA, or employer drug testing.
• Your goal is peak output on race day, not subjective enjoyment in training.
• You have cardiovascular history, anxiety sensitivity, or a technical race requiring sharp reactions.
• You cannot verify batch testing or contamination risk on a product label.

Co-Use May Be A Personal Choice If

• You are an adult in a legal jurisdiction, not subject to testing, and accept ergolytic or neutral performance data.
• You use cannabis to increase adherence on easy days, not to hit workouts that require precise pacing.
• You start low, never drive under influence, and treat commercial products as experiments with unknown individual response.

What PR Run Adds To This Conversation

Cannabis does not replace course-specific training. Heat, altitude, vert, and cutoffs still come from the file. See the heat and altitude pillar for oxygen delivery. See the sauna guide for heat acclimation evidence limits. See foot care for inflammation you can actually see on your skin after long runs.

Enjoyment is not laziness. Neither is it a substitute for a plan tied to the race you entered.

What The Evidence Still Lacks

• Few double-blind, placebo-controlled trials on named commercial athlete formulas with performance endpoints.
• Most cannabis-exercise studies recruit existing users, creating selection bias toward positive subjective reports.
• Product matrix heterogeneity (full spectrum, isolate, emulsion, dose) makes cross-study comparison weak.
• Longitudinal data on injury, overtraining, and race outcomes in co-using ultrarunners are sparse.

What Would Settle The Debate

Crossover RCTs with plasma endocannabinoid assays, power output, pacing strategy, and affect scales on trail-relevant durations. Recovery protocols with NSF-certified CBD in elite athletes. Independent replication of low-dose THC plus CBD combinations at exercise-relevant timing without industry funding.

Until those exist, treat the runner's high as one of the cleaner stories in exercise neuroscience, and cannabis co-use as a culture and adherence story more than a performance story.